Be a Smart Investor

Thursday, October 25, 2018

ALGN Plunges, NVCR's Q3 Revenue Lags Estimate, SELB Continues To Bleed

The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

from RTT - Biotech https://ift.tt/2z3jYRT
via IFTTT

FATE Catches Eyes, LJPC Upbeat, CLSD To Submit XIPERE NDA By Year-end

The following are some of today's top gainers in the pharma/biotech sector.

from RTT - Biotech https://ift.tt/2PlHiV7
via IFTTT

Google Parent Alphabet Q3 Profit Rises, But Sales Miss View; Stock Down

Alphabet Inc. (GOOG, GOOGL), the parent company of Google, Thursday reported a surge in profit for the third quarter, driven largely revenue growth in search and advertising. Earnings for the quarter trumped Wall Street estimates easily, however, revenues fell short of expectations, sending the search giant's stock down by about 5 percent in extended session.

from RTT - Earnings https://ift.tt/2Sj7pec
via IFTTT

Amazon Q3 Sales, Outlook Miss Street Estimates; Shares Down 6%

Amazon.com Inc. (AMZN) Thursday reported a surge in profit for the third quarter, driven largely by a 29 percent jump in revenues. Earnings for the quarter trounced Wall Street estimates. However, the tech giant's stock slipped more than 6 percent in extended session after revenues for the quarter fell short of expectations and on weak outlook for the current holiday quarter.

from RTT - Earnings https://ift.tt/2z7Hptk
via IFTTT

TSX Fails To Hold Gains, Ends Just Marginally Up

The Canadian stock market rebounded on Thursday after recent losses, but despite holding on in positive territory right through the session amid high volatility, ended just marginally higher on Thursday.

from RTT - Market Analysis https://ift.tt/2EOn9mH
via IFTTT

Sears' future in doubt as Chairman Eddie Lampert looks for more protections

Sears Chairman Eddie Lampert has gone to invesmtent banks in past week asking them to improve the terms of his bankruptcy loan. If Sears doesn't get more money, it could burn through cash within two weeks.

from Deals and IPOs https://ift.tt/2OLK4Ui

Regeneron: Eylea Phase 3 Panorama Trial Meets Primary, Secondary Endpoints

Regeneron Pharmaceuticals Inc. (REGN) said that the Phase 3 PANORAMA trial evaluating Eylea (aflibercept) Injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its one-year primary endpoint and key secondary endpoints.

from RTT - Biotech https://ift.tt/2PkwhDv
via IFTTT